SUMMARY Polyethylene glycol (PEG) 4000 is one of numerous substances used as non-absorbable markers to correct for variable faecal output when assessing daily faecal losses of nutrients. The introduction of enteric coated micro-encapsulated pancreatic enzyme (EMPE) preparations has greatly improved the control of fat malabsorption in cystic fibrosis and chronic pancreatitis patients. Unfortunately, these enzyme preparations contain significant quantities of PEG 4000 or polyvinyl pyrolidine (PVP) Radio-opaque pellets were prepared by cutting 1.0-1-5 mm lengths of Portex 2-0 mm internal diameter radio-opaque tubing; these were extracted overnight with toluene to remove the plasticiser and, after drying, were packaged in gelatin capsules, each of which contained eight pellets. For seven days 17 CF patients received 500 mg PEG (Sandoz Products Ltd, London) and eight ROP three times daily, and 11 received only eight ROP three times per day. Normal diet and medication were continued throughout the seven days. During the last 48 hours all stools were collected in separate strong polyethylene bags, which fitted directly on to a commode.
SUMMARY Polyethylene glycol (PEG) 4000 is one of numerous substances used as non-absorbable markers to correct for variable faecal output when assessing daily faecal losses of nutrients. The introduction of enteric coated micro-encapsulated pancreatic enzyme (EMPE) preparations has greatly improved the control of fat malabsorption in cystic fibrosis and chronic pancreatitis patients. Unfortunately, these enzyme preparations contain significant quantities of PEG 4000 or polyvinyl pyrolidine (PVP) as components of the enteric coating and thus PEG 4000 cannot be used either as a faecal marker, or in intubation studies, if these enzyme preparations are being used.
Minimising faecal fat output is essential in the management of cystic fibrosis (CF) if the benefits of the high energy, normal fat diet which is now recommended are to be fully realised. Radio-opaque pellets were prepared by cutting 1.0-1-5 mm lengths of Portex 2-0 mm internal diameter radio-opaque tubing; these were extracted overnight with toluene to remove the plasticiser and, after drying, were packaged in gelatin capsules, each of which contained eight pellets. For seven days 17 CF patients received 500 mg PEG (Sandoz Products Ltd, London) and eight ROP three times daily, and 11 received only eight ROP three times per day. Normal diet and medication were continued throughout the seven days. During the last 48 hours all stools were collected in separate strong polyethylene bags, which fitted directly on to a commode.
Stools were frozen and then x-rayed. Radioopaque pellets were easily distinguished on x-ray films and were counted. The pooled two day collections were then homogenised and analysis was performed for PEG by the method of Malawer6 and for fat by the method of van de Kamer et al.7 Daily faecal fat output was calculated using each marker. mmol) when using ROP as the marker, and from 13-6 mmol to 162-4 mmol (mean 63.2 mmol) when using PEG.
The correlation between PEG and ROP content in the 48 hour faecal collections is shown in the Figure, and it can be seen that despite the close correlation (r=0.87), in all except one of the patients taking pancreatic supplements, there is proportionately more PEG than ROP present. Use of these marker concentrations to calculate daily faecal output results in an error of up to 52% (mean 35%) when PEG was the marker. In the one patient not taking pancreatic supplements, there was only a 6% difference in the results obtained using the two markers.
Two day faecal collections from 11 CF patients taking only ROP as the continuous marker were also analysed for PEG, and contained between 61 mg and 2815 mg of PEG.
The quantity of PEG (or PEG reacting substances) was estimated in a range of medications which are frequently taken by CI patients. These analyses were undertaken on untreated medications and also after incubation with a control faecal homogenate for six hours at 37°C. As seen in the 
